The Role of Squamous Cell Carcinoma Antigen As a Prognostic and Predictive Factor in Carcinoma of Uterine Cervix

Overview

Journal Radiat Oncol J

Specialty Oncology

Date 2012 Sep 18

PMID 22984670

Citations 14

Authors

Bae Kwon Jeong

Doo Ho Choi

Seung Jae Huh

Won Park

Duk Soo Bae

Byoung-Gie Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: Although the role of squamous cell carcinoma antigen (SCC-Ag) as a predictive and prognostic factor for uterine cervical cancer has been identified in previous studies, 1) the effective patient group of screening for recurrence with SCC-Ag, 2) the relationship between SCC-Ag and recurrence site, and 3) the relationship between the change of SCC-Ag and treatment outcome or recurrence have not been described.

Materials And Methods: The study included 506 patients with histologically proven uterine cervical cancer between January 1994 and December 2010. We determining the serum SCC-Ag level before treatment and after treatment, and conducted a retrospective review of the patients' records. We evaluated the sensitivity and specificity of SCC-Ag for the detection of tumor recurrence by comparing biochemical recurrence with clinical recurrence.

Results: The pretreatment SCC-Ag level and the proportion of patients over 1.5 ng/mL were higher in poor prognostic patient group. In the univariate and multivariate analysis, pretreatment SCC-Ag showed a statistically significant correlation with tumor size, International Federation of Gynecology and Obstetrics (FIGO) stage, pathology. In patients with biochemical recurrence vs. those without, 5-year DFS and OS were 27.6 vs. 92.7% (p ≤ 0.001) and 53.7 vs. 92.5% (p ≤ 0.001), respectively.

Conclusion: Our study reconfirmed the known function of pretreatment SCC-Ag, but could not confirm the function of biochemical response as a predictive factor for treatment and as a prognostic factor. There was no statistically significant relationship between SCC-Ag level and recurrence site. We confirmed the role of SCC-Ag as a follow-up tool for recurrence of disease and which patient groups SCC-Ag was more useful for.

Citing Articles

Circulating tumor cells in patients with cervical cancer undergoing chemoradiotherapy combined with brachytherapy.

Reginacova K, Pospisilova E, Kubecova M, Svobodova P, Bobek V, Kolostova K Am J Cancer Res. 2024; 14(7):3614-3625.

PMID: 39113856 PMC: 11301293. DOI: 10.62347/QIXJ7103.

Prognostic value of HPV circulating tumor DNA detection and quantification in locally advanced cervical cancer.

Beaussire-Trouvay L, Duhamel O, Perdrix A, Leveque E, Vion R, Rovelet-Lecrux A Front Oncol. 2024; 14:1382008.

PMID: 39040450 PMC: 11260666. DOI: 10.3389/fonc.2024.1382008.

Contrast-enhanced ultrasound combined with elastic imaging for predicting the efficacy of concurrent chemoradiotherapy in cervical cancer: a feasibility study.

Ma Y, Zhao X, Chen X Front Oncol. 2024; 14:1301900.

PMID: 38634056 PMC: 11021703. DOI: 10.3389/fonc.2024.1301900.

Fatty acid metabolism: A new therapeutic target for cervical cancer.

Ping P, Li J, Lei H, Xu X Front Oncol. 2023; 13:1111778.

PMID: 37056351 PMC: 10088509. DOI: 10.3389/fonc.2023.1111778.

Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer.

Chen W, Xiu S, Xie X, Guo H, Xu Y, Bai P Radiat Oncol. 2022; 17(1):6.

PMID: 35012582 PMC: 8751300. DOI: 10.1186/s13014-021-01978-0.

References

Esajas M, Duk J, de Bruijn H, Aalders J, Willemse P, Sluiter W . Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol. 2001; 19(19):3960-6. DOI: 10.1200/JCO.2001.19.19.3960. View

Forni F, Ferrandina G, Deodato F, Macchia G, Morganti A, Smaniotto D . Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness. Int J Radiat Oncol Biol Phys. 2007; 69(4):1145-9. DOI: 10.1016/j.ijrobp.2007.04.055. View

Ogino I, Nakayama H, Okamoto N, Kitamura T, Inoue T . The role of pretreatment squamous cell carcinoma antigen level in locally advanced squamous cell carcinoma of the uterine cervix treated by radiotherapy. Int J Gynecol Cancer. 2006; 16(3):1094-100. DOI: 10.1111/j.1525-1438.2006.00449.x. View

Reesink-Peters N, van der Velden J, ten Hoor K, Boezen H, de Vries E, Schilthuis M . Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer. J Clin Oncol. 2005; 23(7):1455-62. DOI: 10.1200/JCO.2005.02.123. View

Benedet J, Odicino F, Maisonneuve P, Beller U, Creasman W, Heintz A . Carcinoma of the cervix uteri. J Epidemiol Biostat. 2001; 6(1):7-43. View

Maiman M . The clinical application of serum squamous cell carcinoma antigen level monitoring in invasive cervical carcinoma. Gynecol Oncol. 2001; 84(1):4-6. DOI: 10.1006/gyno.2001.6532. View

Gadducci A, Tana R, Fanucchi A, Genazzani A . Biochemical prognostic factors and risk of relapses in patients with cervical cancer. Gynecol Oncol. 2007; 107(1 Suppl 1):S23-6. DOI: 10.1016/j.ygyno.2007.07.033. View

Ohno T, Nakayama Y, Nakamoto S, Kato S, Imai R, Nonaka T . Measurement of serum squamous cell carcinoma antigen levels as a predictor of radiation response in patients with carcinoma of the uterine cervix. Cancer. 2003; 97(12):3114-20. DOI: 10.1002/cncr.11453. View

Ferrandina G, Macchia G, Legge F, Deodato F, Forni F, Digesu C . Squamous cell carcinoma antigen in patients with locally advanced cervical carcinoma undergoing preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome. Oncology. 2008; 74(1-2):42-9. DOI: 10.1159/000138979. View

10.

Micke O, Prott F, Schafer U, Tangerding S, Potter R, Willich N . The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res. 2001; 20(6D):5113-5. View

11.

Ohara K, Tanaka Y, Tsunoda H, Nishida M, Sugahara S, Itai Y . Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging. Obstet Gynecol. 2002; 100(4):781-7. DOI: 10.1016/s0029-7844(02)02204-4. View

12.

Gaarenstroom K, Kenter G, Bonfrer J, Korse C, van de Vijver M, Fleuren G . Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?. Gynecol Oncol. 2000; 77(1):164-70. DOI: 10.1006/gyno.2000.5732. View

13.

Classe J, Rauch P, Rodier J, Morice P, Stoeckle E, Lasry S . Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer). Gynecol Oncol. 2006; 102(3):523-9. DOI: 10.1016/j.ygyno.2006.01.022. View

14.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

15.

Hirakawa M, Nagai Y, Inamine M, Kamiyama K, Ogawa K, Toita T . Predictive factor of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy. Gynecol Oncol. 2007; 108(1):126-9. DOI: 10.1016/j.ygyno.2007.08.091. View

16.

Scambia G, Benedetti Panici P, Foti E, Amoroso M, Salerno G, Ferrandina G . Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer. J Clin Oncol. 1994; 12(11):2309-16. DOI: 10.1200/JCO.1994.12.11.2309. View

17.

Molina R, Filella X, Lejarcegui J, Pahisa J, Torne A, Rovirosa A . Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumour Biol. 2003; 24(3):156-64. DOI: 10.1159/000073846. View

18.

Chou H, Wang C, Lai C, Hong J, Ng K, Chang T . Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma. Int J Radiat Oncol Biol Phys. 2001; 51(2):442-8. DOI: 10.1016/s0360-3016(01)01628-5. View

19.

Ferrandina G, Legge F, Fagotti A, Fanfani F, DiStefano M, Morganti A . Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome, and prognostic measures. Gynecol Oncol. 2007; 107(1 Suppl 1):S127-32. DOI: 10.1016/j.ygyno.2007.07.006. View

20.

Lai C . Management of recurrent cervical cancer. Chang Gung Med J. 2005; 27(10):711-7. View